BioTuesdays

Tag - BCLI

Brainstorm Cell Therapeutics Logo

BrainStorm NurOwn flunks Phase 3 ALS trial

BrainStorm Cell Therapeutics’ (NASDAQ:BCLI) NurOwn failed to meet its primary and secondary endpoints in a Phase 3 amyotrophic lateral sclerosis (ALS) trial. NurOwn consists of mesenchymal stromal cells (MSCs) that have...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.